BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, January 18, 2026
Home » Authors » Mark McCarty

Articles by Mark McCarty

Washington roundup: FDA's mobile medical app draft may allow class III designation

Aug. 3, 2011
By Mark McCarty

Washington roundup: Experts: device makers need to write social media policies

Aug. 2, 2011
By Mark McCarty

IOM's proposal to scrap the 510(k) is kaput: What's next?

Aug. 1, 2011
By Mark McCarty
In today's edition of Medical Device Daily, I write that the proposal by the Institute of Medicine to trash the 510(k) mechanism in favor of a brand new scheme is impractical and will gain no traction. Not only does industry find this impossible to choke down, but even Jeff Shuren, MD, director of FDA's Center for Devices and Radiological Health, remarked that FDA believes “that the 510(k) process should not be eliminated,” although Shuren said he and his team are “open to additional proposals” for “continued improvement.” One caveat to the rejection of the IOM proposal is that even though...
Read More

FDA's new nanoscale materials guidance sets bar at 1,000 nm

Aug. 1, 2011
By Mark McCarty

Washington roundup: IOM recommendations seen as too speculative to gain traction

Aug. 1, 2011
By Mark McCarty
Now that the Institute of Medicine (IOM) has fulfilled its task of making recommendations for the 510(k) program at FDA, all parties have had a chance to respond to at least the broad strokes of the IOM recommendations. The long-awaited report recommends that FDA dump the 510(k) program and start over. However, while the suggestion has plenty of critics in industry, even FDA indicates it has no intention whatsoever of making such a move. (Medical Device Daily)
Read More

Device user fee discussions heading nowhere fast

July 29, 2011
By Mark McCarty
If you enjoy participating vicariously in exercises in futility, take a gander at what's going on in Washington with regard to user fees for medical device reviews. Yesterday, Sen. Richard Burr (R-North Carolina) told FDA commish Margaret Hamburg, MD, than any user fee legislation that does not incorporate non-FDA days into the calculation of total 510(k) review days would face “a long and laborious process” to get the required legislation through the Senate Health, Education, Labor and Pensions Committee. Burr's position was essentially that FDA has not met the turn-around on applications called for in the previous user fee handshake,...
Read More

Washington roundup: Senate HELP committee shows ideological divide on user fees

July 29, 2011
By Mark McCarty

Washington roundup: CMS assumes GDP growth of 4.7% yearly for next 10 years

July 28, 2011
By Mark McCarty

Washington roundup: FDA's 'when-to-file' guidance limits predicates to those cited

July 27, 2011
By Mark McCarty

Three clichés that make my skin crawl

July 26, 2011
By Mark McCarty
Ah, clichés. They're the stuff life is made of, eh? There's always the danger of resorting to them in my line of work. When I see them in my own copy, I feel a little like Harvey Korman's character in the Mel Brooks classic film “Blazing Saddles.” Korman's character is Hedley Lamarr (It's not Hedy, it's Hedley!!), the evil state attorney general who recoils at the use of the cliché “head them off at the pass.” “I HATE that cliché,” Lamarr said in disgust. Lamarr might have been a fictional...
Read More
Previous 1 2 … 453 454 455 456 457 458 459 460 461 … 578 579 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 16, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing